Edgewise Therapeutics reports positive results for muscular dystrophy treatment

Edgewise Therapeutics Inc. (NASDAQ:EWTX) is a top stock to invest in now with positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. Sevasemten maintained a favorable safety profile over 3 years for Becker muscular dystrophy. The Phase 2 LYNX and FOX trials showed encouraging data for Duchenne muscular dystrophy. Sevasemten is a fast skeletal myosin inhibitor for muscular dystrophies with no current therapies. Becker affects males, while Duchenne has a median life expectancy of 30 years. EWTX focuses on muscle disorder therapies but other AI stocks may offer better investment opportunities.

Read more at Yahoo Finance: Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment